TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Development of Stimulator Pneumatic for Realization of Evoked Potential Allodynic/Somatosensory

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria of patients :~* Major Patient~* Patient affiliated or entitled to a social security scheme~* Patient with neuropathic pain authenticated by the neurologist, with the presence of allodynia.~* Patient has given its written consent to participate in the study~Exclusion Criteria of patients :~* Diseases affecting the nervous system,~* Diabetes,~* Patients who received chemotherapy~* Pregnant woman~* Nobody in emergencies~* A person unable to give consent~Inclusion Criteria of healthy volunteers :~* Major subject~* Subject affiliated or entitled to a social security scheme~* Subject has given its consent to participate in the study~Exclusion Criteria of healthy volunteers :~* Diseases affecting the nervous system,~* Diabetes,~* Patients who received chemotherapy~* Pregnant woman~* Nobody in emergencies~* A person unable to give consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- patient with neuropathic pain with allodynia (Type: EXPERIMENTAL): None
- healthy volunteers (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Web-based Attention Bias Modification Treatment for Childhood Anxiety Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible for participation are children (aged 8 to 16 years)~* Primary diagnosis of separation anxiety disorder,~* Primary diagnosis of generalized anxiety disorder~* Primary diagnosis of specific phobia~* Primary diagnosis of social phobia~Exclusion Criteria:~* IQ below 85~* poor command of the Dutch language~* serious physical disease~* psychosis~* substance abuse~* pervasive developmental disorder~* obsessive-compulsive disorder~* posttraumatic stress disorder~* acute stress disorder~* panic disorder~* major depression~* anxiety medication during treatment~* any concurrent psychotherapy

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Combined ABMT and CBT (Type: EXPERIMENTAL): 9 sessions of Attention Bias Modification Treatment (dot-probe based of 160 trials) followed by individual Cognitive Behavioral Therapy via FRIENDS program
- Combined Sham ABMT and CBT (Type: SHAM_COMPARATOR): 9 sessions of Sham Attention Bias Modification Treatment (dot-probe based of 160 trials) followed by individual Cognitive Behavioral Therapy via FRIENDS program

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Fundic Gland Polyps and Proton Pump Inhibitor (PPI) Drugs

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 and above.~* Able and willing to sign informed consent.~* The patient had a gastric fundic gland polyp detected on EGD that was removed and sent to pathology or patient had no fundic gland polyps on EGD but are on PPIs and will serve as controls.~Exclusion Criteria:~* Unwilling or unable to sign informed consent for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Fundic Gland Polyps on PPI (Type: None): Patients found to have fundic gland polyps on endoscopic evaluation that have also been prescribed and regularly take a proton pump inhibitor.
- Fundic Gland Polyp not on PPI (Type: None): Patients found to have fundic gland polyps on endoscopic evaluation that have not been prescribed a proton pump inhibitor.
- Group 3 (Control Group) (Type: None): Individuals who are prescribed proton pump inhibitor but are not found to have fundic gland polyps on endoscopic evaluation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stable New York Heart Association (NYHA) Class II-IV heart failure symptoms for at least 4 weeks before study entry~* Diagnosis of diastolic heart failure with a normal ejection fraction~* Admitted to the hospital with a diagnosis of heart failure in the 12 months before study entry~* Type 2 diabetes~Exclusion Criteria:~* Unstable angina, heart attack, coronary artery bypass surgery, or angioplasty in the 3 months before study entry~* Angina with exertion~* Technically inadequate echocardiogram~* Atrial fibrillation or atrial flutter~* Severe valvular heart disease~* Significant kidney insufficiency (serum creatinine greater than 2.0 mg/dL or require hemodialysis)~* Conditions that may be associated with changes in markers of fibrosis or collagen turnover (e.g., ongoing or active rheumatological disease, requiring significant anti-inflammatory agents, immunosuppression, pulmonary fibrosis, active cancer)~* Significant history of active substance abuse~* Type 1 diabetes~* Type 2 diabetes requiring chronic insulin use before study entry~* Active thiazolidinedione (TZD) use, because TZDs have been shown to worsen volume retention and may exacerbate signs and/or symptoms of heart failure~* Pregnant or breastfeeding~* Hypertrophic cardiomyopathy

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: NO_INTERVENTION): Participants will receive usual care for 12 weeks. The care will be dictated by the primary physician and/or diabetologist caring for the participant. Efforts will be made to ensure that all participants receive standard measures as indicated by guidelines, with a particular emphasis on blood pressure control and glucose control.
- 2 (Type: EXPERIMENTAL): Participants will receive exenatide for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Transvaginal Repair for Rectocele

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women~* Older than 18 year old~* Symptoms of obstructed defecation associated to a rectocele with an indication for surgery according to the following criteria:~  1. Symptoms of obstructed defecation according to Rome III criteria: straining, sensation of incomplete evacuation, sensation of anorectal obstruction/blockage, and/or manual manoeuvres to facilitate defecation at least in 25% of defecations for the last 3 months~ 2. Incomplete emptying of the rectocele on a defecography~ 3. Failure of conservative treatment including dietary advice and laxatives, with persisting symptoms of obstructive defecation~ 4. Recto-rectal intussusception may coexist on defecography (grade I and II of Oxford Prolapse Grading System)~ 5. Non-obstructive enterocele may coexist on defecography (type A enterocele: the small bowel descends to puboccoccygeal line (PCL) during straining and returns to PCL at the end of the straining attempt without compressing the rectal ampulla or compressing it from above with no obstruction)~ 6. Absence of anal sphincter dyssynergia on anorectal manometry, or successful rehabilitation after biofeedback in the case of previous dyssynergia~* Ability to understand the surgical procedure and the questionnaires of the study~* Written informed consent~Exclusion Criteria:~* Anal sphincter dyssynergia~* Coexisting recto-anal intussusception on defecography or external rectal prolapse (grades III, IV and V Oxford Prolapse Grading System)~* Coexisting enterocele compressing/obstructing the rectum on defecography (type B enterocele: the enterocele descends beyond the PCL to the perineum through the rectovaginal space to compress the rectal ampulla at the end of the evacuation process; type C enterocele (obstructive): the enterocele descends beyond the PCL to the perineum through the rectovaginal space to compress the rectal ampulla at the beginning of the evacuation process)~* Slow transit constipation associated to obstructed defecation~* Severe psychiatric disorder~* Refusal to provide written informed consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mortality Due to Malignancy in Patients With Idiopathic Venous Thromboembolism

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Proven first symptomatic deep venous thromboembolic event;~* No known malignancy~* Without: trauma of the legs, surgery within the last 2 months, immobilization within the last 2 months, thrombocytosis (\> 1000 x 109), clinical severe dehydration, deficiency of anti-thrombin III, protein C/S, Factor V Leiden mutation , Prothrombine mutation or circulating lupus anticoagulants, pregnancy or post-partum period~* No indication for malignancy at routine investigations(medical history, physical examination, routine blood tests and chest X-ray)~Exclusion Criteria:~* Proven deep venous thromboembolic event in the medical history~* age under 40 years;

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IVTE, follow-up (Type: None): no malignancy at basal screening, no extensive screening
- IVTE, screening (Type: None): No malignancy at basal screening, screening by means of CT-Chest/abdomen and mammography in women

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Diagnosis and Monitoring of Eosinophilic Esophagitis Using the Cytosponge

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able to read, comprehend, and complete the informed consent form~* Male or female subjects, age 18-80 years,~* Suspected EoE or has a diagnoses of EoE with current active disease,~Exclusion Criteria:~* History of esophageal stricture precluding passage of the endoscope or sponge,~* Pregnancy, or planned pregnancy during the course of the study,~* Any history of esophageal varices, liver impairment of moderate or worse severity (Child's- Pugh class B \& C) or evidence of varices noted on any past endoscopy,~* Any history of esophageal surgery, except for uncomplicated fundoplication~* History of coagulopathy, with international normalized ratio (INR) \>1.3 and/or platelet count of \<75,000.~* Current use of blood thinners such as coumadin, warfarin, clopidogrel, heparin and/or low molecular weight heparin (requires discontinuation of medication 7 days prior to and 7 days after esophagogastroduodenoscopy (EGD) and Cytosponge administration, aspirin use is OK).~* Are allergic to local anesthetics such as lidocaine (these subjects may opt not to receive the optional lidocaine gargle prior to the Cytosponge administration and still be eligible).~* Have not fasted the night before administration of the Cytosponge.~* History of perforation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- EoE Patients (Type: EXPERIMENTAL): Patients who have been diagnosed with EoE as per recent guidelines will be enrolled. Samples will be obtained using the Cytosponge™ Cell Collection Device (Cytosponge) prior to participants' routine endoscopy with biopsy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of MF with bone marrow fibrosis of at least Grade 1; irrespective of JAK2 mutational status~* Patients with at least one mutation in one of the five HMR genes (ASXL1, EZH2, SRSF2 and IDH1/2)~* Patients with non-palpable spleen or spleen palpable ≤ 5 cm from the left costal margin to the point of greatest splenic protrusion~* Patients with MF-7 score of ≤ 15, with each individual symptom score of ≤ 3~Exclusion Criteria:~* Patients with prior treatment with ruxolitinib or other JAK inhibitors.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib (Type: ACTIVE_COMPARATOR): Two tablets of ruxolitinib 5 mg were administered orally twice per day.
- Ruxolitinib Placebo (Type: PLACEBO_COMPARATOR): Two tablets of 5mg placebo were administered orally twice per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Rhegmatogenous retinal detachment~* Central vision affected for less than 72 hours~* Pseudophakic~* Age 18 or over~* Not participating in other clinical trials~* Willing to attend follow-up visits~* Written informed consent~Exclusion Criteria~* Phakic~* Narrow angle glaucoma~* Previous intraocular surgery other than cataract operation~* Retinal disease~* Concurrent treatment with MAO inhibitors~* Pregnancy~* Malignant arterial hypertension~* Liver or kidney failure~* Life-threatening or malignant disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Patients getting perioperative oral treatment with rasagiline (1mg daily) for 7 days
- Control (Type: PLACEBO_COMPARATOR): Patients getting perioperative oral treatment with placebo for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Car Safety Seat and Gastroesophageal Reflux Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion criteria were: healthy term-born infants between two weeks and six months old suspected to have GERD, in general good health. The infants did not need to meet the criteria for GERD to be eligible.~Exclusion Criteria:~* Exclusion criteria were infants with psychomotor retardation, acute illness or contra-indication for pH monitoring.

- Gender: ALL
- Minimum Age: 2 Weeks
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- lifestyle counseling (Type: NO_INTERVENTION): The positions in the car safety seat and in supine 15 degrees anti-Trendelenburg are compared on the basis of a 20 hour pH monitoring. In one group the infants were first continuously positioned at 45 degrees elevation in a car safety seat (car safety seat type Maxi cosi Citi for infants from 0-13kg). During the next period the infants were kept in a supine 15 degrees anti-Trendelenburg position (hospital infant bed), and vice versa for the other group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Efficacy of Lateral Heel Wedges of Osteoarthritis of the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients 30 years or older with medial compartment knee Osteoarthritis (unilateral) and Grade 4 Kellgren-Lawrence39 radiographic changes presenting for treatment of knee pain.~* Range of motion knee-flexion beyond 100 degrees and not lacking more than 15 degrees of extension.~* Subtalar and forefoot motion permitting foot/ankle eversion with weight bearing.~* Sufficient shoe toe box height to allow space for the insole and therefore comfort and compliance.~* Passive laxity of medial capsule and collateral ligament by knee extension test.~Exclusion Criteria:~* All other forms of knee arthritis other than OA.~* Knee Instability- medial pseudo-opening of greater than grade 1 or detectable Anterior-posterior instability.~* Less than Grade 4 Kellgren-Lawrence radiographic changes in the medial compartment of the knee39.~* Grade 2 or greater Kellgren-Lawrence radiographic39 involvement of the patellofemoral or lateral compartment.~* Inadequate knee range of motion~* Balance problems requiring the use of a walker or wheel chair - ambulation with aid~* Diabetics with peripheral neuropathy~* Knee surgery within the past year~* Intraarticular steroid injection or visco supplementation within 6 months~* Stiff subtalar or forefoot joints - clinical test~* Inadequate shoe toe box depth to accommodate the test or control inserts~* Charcot joint~* Fixed contracture of the medial capsule and/or collateral ligament- clinical test

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 100 Years
- Healthy Volunteers: t

Study Arms:
- Wedge Insert (Type: EXPERIMENTAL): Patients will receive a wedge insert
- Flat insert (Type: PLACEBO_COMPARATOR): Patients will receive a flat insert

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Hospitalized with coronavirus disease 2019 (COVID-19) pneumonia confirmed by World Health Organization criteria.~* Oxygen saturation ≤ 94% at room air or arterial partial pressure of oxygen/fraction of inspired oxygen \< 300 mm Hg and \> 200 mm Hg.~* Negative influenza test.~* Lymphocyte counts \< 10\^3/μL and the presence of at least one of the following markers of hyperinflammation within 1 day prior to VIB7734 administration:~  * Elevated high sensitivity C-reactive protein (hsCRP) \> 50 mg/L~ * Ferritin \> 500 ng/mL~ * Lactate dehydrogenase (LDH) \> 300 U/L~ * D-dimers \> 500 ng/mL~NOTE: Other protocol defined inclusion criteria apply~Key Exclusion Criteria:~* Respiratory failure requiring mechanical ventilation.~* In the opinion of the Investigator, progression to mechanical ventilation or death is imminent and inevitable within the next 24 hours.~* Valid Do Not Intubate (DNI) or Do Not Resuscitate (DNR) order.~* Anticipated duration of hospital stay \< 72 hours.~* History of allergy or hypersensitivity reaction to any component of the IP.~* Participation in another clinical study with an IP within 4 weeks prior to Day 1 or within 5 half-lives of the IP, whichever is longer. (Participation in COVID-19 antiviral or antimalarial trials may be permitted after discussion with the Medical Monitor).~* Liver cirrhosis or liver failure.~* Known human immunodeficiency virus infection.~* Known hepatitis B or known hepatitis C infection in the absence of a history of curative therapy.~* Known or suspect active or latent tuberculosis infection.~* Active bacterial, fungal, viral, or other infection (besides COVID-19).~* Clinically significant cardiac disease within 6 months.~* History of severely impaired respiratory function at baseline (not related to COVID-19) based on requirement for home oxygen of \> 4 L/min or based on other medical history known to the Investigator.~* History of cancer within 12 months of enrollment.~* Receipt of chemotherapy, biologic immunomodulators (including JAK inhibitors), or immunosuppressive therapies within 8 weeks of enrollment, or receipt of rituximab or other B cell-depleting mAb therapy within 6 months.~NOTE: Other protocol defined exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- VIB7734 Dose (Type: EXPERIMENTAL): Participants will receive a single subcutaneous dose of VIB7734.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive a single subcutaneous dose of placebo (saline) matched to single dose of VIB7734.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy